CABALETTA BIO INC. - COMMON STOCK

Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer

11 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

10 Jan 2022 08:00:04 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris

14 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in November

09 Nov 2021 16:30:00 By Nasdaq GlobeNewswire

Cabaletta Bio Expands Executive Leadership Team with Appointments of Samik Basu, M.D. to Chief Scientific Officer and Heather Harte-Hall, MSc. to Chief Compliance Officer

09 Nov 2021 08:00:04 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update

01 Nov 2021 07:05:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV

01 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021

15 Oct 2021 16:30:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the Chardan 5th Annual Genetic Medicines Conference

28 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel

07 Sep 2021 08:00:03 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV

18 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Second Quarter 2021 Financial Results and Provides Business Update

05 Aug 2021 07:30:01 By Nasdaq GlobeNewswire

Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors

28 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the Jefferies Healthcare Conference

27 May 2021 08:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates

03 May 2021 07:05:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial

03 May 2021 07:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 20th Annual Needham Healthcare Conference

07 Apr 2021 08:00:02 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update

16 Mar 2021 07:30:01 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

23 Feb 2021 08:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

07 Jan 2021 08:00:01 By Nasdaq GlobeNewswire